GlassScriptPhysician profile
Heath A Lindsey
NPI 1578048708
$1,993.44
in general payments reported to CMS, 2019-2025
20 companies · $922 in 2025
The $922 reported for 2025 was more than what 79% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $30.07 · 2022: $241 · 2023: $362 · 2024: $438 · 2025: $922.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,722.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,722.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $402.18 | 2022-2025 | Uzedy, Austedo Xr, Austedo |
| Janssen Pharmaceuticals, INC | $265.13 | 2022-2025 | Invega Sustenna, Spravato, Invega Trinza |
| Alkermes, INC. | $258.31 | 2021-2025 | Aristada, Lybalvi, Vivitrol |
| Neurocrine Biosciences, INC. | $246.89 | 2022-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $205.34 | 2023-2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Astrazeneca Pharmaceuticals LP | $80.31 | 2024-2025 | Breztri, Airsupra |
| Glaxosmithkline, LLC. | $76.05 | 2025 | Trelegy Ellipta |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $57.18 | 2023-2025 | Caplyta |
| Xeris Pharmaceuticals, INC. | $54.62 | 2024 | Gvoke Hypopen |
| Boehringer Ingelheim Pharmaceuticals, INC. | $53.50 | 2022 | |
| Mylan Specialty L.P. | $43.16 | 2021-2024 | Yupelri |
| Biohaven Pharmaceutical Holding Company LTD. | $41.51 | 2022 | |
| Exact Sciences Corporation | $37.66 | 2023-2025 | Cologuard Collection Kit |
| Lundbeck LLC | $37.29 | 2023 | Vyepti |
| Vanda Pharmaceuticals INC. | $36.25 | 2025 | Fanapt |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Agios Pharmaceuticals, INC. | $32.89 | 2022 | |
| Pfizer INC. | $19.42 | 2023 | |
| Astellas Pharma US INC | $17.06 | 2024 | Veozah |
| Lilly USA, LLC | $14.71 | 2025 | Jardiance |
| Viatris Specialty LLC | $13.98 | 2025 | Yupelri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heath Lindsey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.